DOI: https://doi.org/10.25251/skin.4.6.0

Published: 2020-11-15

In-Depth Reviews

A Systematic Review of Neurovascular Complications in Patients with Pseudoxanthoma Elasticum

Colin Domzalski, Nancy Wei, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.4.6.1

Page 491-496

PDF

Original Research

Analyzing the Relationship Between Altmetric Score and Literature Citations in the Dermatology Literature

Meredith E Thomley, Ana Preda-Naumescu, Carter J Boyd, Tiffany Mayo
| DOI https://doi.org/10.25251/skin.4.6.2

Page 497-505

PDF

Development and Validation of a Diagnostic 35-Gene Expression Profile Test for Ambiguous or Difficult-to-Diagnose Suspicious Pigmented Skin Lesions

Sarah Estrada, Jeffrey Shackelton, Nathan Cleaver, Natalie Depcik-Smith, Clay Cockerell, Stephen Lencioni, Howard Martin, Jeffrey Wilkinson, Lauren Meldi Sholl, Michael Berg, Brooke Russell, Olga Zolochevska, Kyle Covington, Aaron Farberg, Matthew Goldberg, Pedram Gerami, Gregory Hosler
| DOI https://doi.org/10.25251/skin.4.6.3

Page 506-522

PDF

A 35-Gene Expression Profile Test for use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists

Aaron Farberg, Kelli Ahmed, Christine Bailey, Brooke Russell, Kelly Douglas, Clare Johnson, Olga Zolochevska, Robert Cook, Matthew Goldberg
| DOI https://doi.org/10.25251/skin.4.6.4

Page 523-533

PDF

An Update on the Global Burden and Socioeconomics of Scabies

Katelyn Urban, Rachel Lynn Giesey, Maria Delost, Gregory Raymond Delost
| DOI https://doi.org/10.25251/skin.4.6.5

Page 534-542

PDF

Factors Influencing Patient Satisfaction in Dermatology

Abigail Cline, Tamar Gomolin, Bijan Safai
| DOI https://doi.org/10.25251/skin.4.6.6

Page 543-547

PDF

Research Letters

755-nm Alexandrite Laser for the Treatment of Non-Facial Superficial and Nodular Basal Cell Carcinoma

Valerie Shiu, Margaret Brown, Pavela Bambekova, Jenny Yeh, Jaqueline Brogan, Catherine Kowalewski
| DOI https://doi.org/10.25251/skin.4.6.7

Page 548-551

PDF

High Demand: Identification of Dermatology Visit Trends from 1991-2016 National Ambulatory Medical Care Surveys

Jade Conway, Bipasha Roy, Lauren Barazani, Albert Wu, Abigail Cline, Janet Moy
| DOI https://doi.org/10.25251/skin.4.6.8

Page 552-555

PDF

A Cross-Sectional Study on Herpes Zoster Diagnosis in the time of COVID-19

| DOI https://doi.org/10.25251/skin.4.6.9

Page 556-558

PDF

Brief Articles

Merkel Cell Carcinoma Presenting as an Indurated Plaque

Margaret Coleman Maxi, Joel Byrne, Ardenne Martin, Pamela Martin
| DOI https://doi.org/10.25251/skin.4.6.10

Page 559-562

PDF

Recurrence of Primary Cutaneous Anaplastic Large Cell Lymphoma at a New Location After Wide Surgical Excision

Payvand Kamrani, Madeline Schaeffer, David Altman
| DOI https://doi.org/10.25251/skin.4.6.11

Page 563-566

PDF

Indurated and Puckered Skin on the Lateral Thighs

Hiren Kolli, Ronald Moy
| DOI https://doi.org/10.25251/skin.4.6.12

Page 567-570

PDF

Palmoplantar Pityriasis Rosea

Aurel Apple, Ann Lin, Angela Kim, Suzanne Rozenberg, Rachel Kushner
| DOI https://doi.org/10.25251/skin.4.6.13

Page 571-574

PDF

Complete Histologic Response of Regionally Metastatic Melanoma Treated with Intralesional Interleukin 2, Topical Retinoid and Imiquimod

William Schaffenburg, Joshua Davis, Nicholas Logemann, Meagan Simpson
| DOI https://doi.org/10.25251/skin.4.6.14

Page 575-578

PDF

Anti-SAE1 Antibodies and Dermatomyositis: A Case Series of Three Patients

Claire Wilson, Brandon Roman, Kurt Ashack, Iris K Aronson
| DOI https://doi.org/10.25251/skin.4.6.15

Page 578-584

PDF

Cutaneous Toxicities of PI3K Inhibitors: A Series of Two Cases and Review of the Literature

Simran Arinder Chadha, Jennifer Shastry, Joel Sunshine, Jennifer Choi, Lauren Guggina
| DOI https://doi.org/10.25251/skin.4.6.16

Page 585-590

PDF

Mycobacterium Kansasii Infection Overlying Tattoo Pigment in an Immunocompromised Patient

Rohit Gupta, Jennifer Martin, Carina Wasko
| DOI https://doi.org/10.25251/skin.4.6.17

Page 591-594

PDF

Painful Retiform Purpura with Cutaneous Necrosis

Alfredo Siller Jr., Joseph Jebain, Yomna Amer, Christopher T. Haley, Leon Chen, Stephen K. Tyring
| DOI https://doi.org/10.25251/skin.4.6.18

Page 595-598

PDF

Primary Cutaneous Mucinous Carcinoma of the Nasal Bridge

Leon Kou, Lily Zhong, Sid Danesh
| DOI https://doi.org/10.25251/skin.4.6.19

Page 599-602

PDF

Ixekizumab Overdose: A Case Report

Margaret L. Snyder, MD, Mark G. Lebwohl, MD
| DOI https://doi.org/10.25251/skin.4.6.20

Page 603-607

PDF

A Rapidly Enlarging Solitary Infantile Myofibroma

Stephany Vittitow, Merrick Kozak, Reza Daughtery, Barrett Zlotoff
| DOI https://doi.org/10.25251/skin.4.6.21

Page 608-612

PDF

Elephantiasis Nostras Verrucosa

Graham H Litchman, Lauren Schwartzberg, Suzanne Friedler, Suzanne Sirota Rozenberg
| DOI https://doi.org/10.25251/skin.4.6.22

Page 613-616

PDF

Short Communications

Onychomadesis as a Manifestation of Coxsackievirus A6 in an Adult

| DOI https://doi.org/10.25251/skin.4.6.23

Page 617-619

PDF

Eccrine Porocarcinoma Masquerading as Squamous Cell Carcinoma

Drew Kuraitis, Yong Lee, Abida Kadi, Andrea Murina
| DOI https://doi.org/10.25251/skin.4.6.24

Page 620-622

PDF

Compelling Comments

Integrating Metagenomics into Personalized Medicine in Dermatology

Amy Huang, Sharon Glick
| DOI https://doi.org/10.25251/skin.4.6.25

Page 623-625

PDF

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Leon Kircik, Mark Lebwohl, Kim Papp, Melinda Gooderham, Linda Stein Gold, Zoe Draelos, Steven Kempers, Stephen Tyring, Lorne Albrecht, Marni Wiseman, Laura Ferris, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk
| DOI https://doi.org/10.25251/skin.4.supp.70

Page s70

Poster PDF

Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Linda Stein Gold, Mark Lebwohl, Kim Papp, Melinda Gooderham, Leon Kircik, Zoe Draelos, Steven Kempers, David Pariser, Javier Alonso-Llamazares, Darryl Toth, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk
| DOI https://doi.org/10.25251/skin.4.supp.71

Page s71

Poster PDF

Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis

Alan Menter, Andrew Blauvelt, Bruce Strober, Matthew Colombo, Renata Kisa, Sudeep Kundu, Subhashis Banerjee, Craig Leonardi
| DOI https://doi.org/10.25251/skin.4.supp.72

Page s72

Poster PDF

An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis

| DOI https://doi.org/10.25251/skin.4.supp.73

Page s73

Poster PDF

Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis

John Jett, Michael McLaughlin, Mark Lee, Lawrence Parish, Glenn Tabolt, Timothy Wilson, Matthew Somerville, Wayne DellaMaestra, Stephen Piscitelli
| DOI https://doi.org/10.25251/skin.4.supp.74

Page s74

Poster PDF

Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette
| DOI https://doi.org/10.25251/skin.4.supp.75

Page s75

Poster PDF

Treatment Success in Mild Psoriasis Patients With Fixed-Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam: Results From the PSO-FAST Trial

Karen Veverka, Jes Hansen, Maria Yaloumis, Leon Kircik, Linda Stein Gold
| DOI https://doi.org/10.25251/skin.4.supp.76

Page s76

Poster PDF

Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis

Adelaide Hebert, Rhonda Schrieber, Debbie Glaab, Lawrence Eichenfield
| DOI https://doi.org/10.25251/skin.4.supp.77

Page s77

Poster PDF

Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area

Craig Leonardi, Linda Stein Gold, Edward Lain, Andrea Neimann, Abby Jacobson
| DOI https://doi.org/10.25251/skin.4.supp.78

Page s78

Poster PDF

Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion

Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai
| DOI https://doi.org/10.25251/skin.4.supp.79

Page s79

Poster PDF

Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

A Blauvelt, RB Warren, K Reich, F Brock, F Fierens, V Ciaravino, M Lebwohl
| DOI https://doi.org/10.25251/skin.4.supp.80

Page s80

Poster PDF

Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)

K Gordon, RB Warren, AB Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, K Reich
| DOI https://doi.org/10.25251/skin.4.supp.81

Page s81

Poster PDF

Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study

K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl
| DOI https://doi.org/10.25251/skin.4.supp.82

Page s82

Poster PDF

Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal

K Gordon, P Foley, JG Krueger, A Pinter, K Reich, R Vender, V Vanvoorden, C Madden, L Peterson, A Blauvelt
| DOI https://doi.org/10.25251/skin.4.supp.83

Page s83

Poster PDF

Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

AB Gottlieb, A Blauvelt, D Tha?i, Y Poulin, F Brock, C Arendt, M Boehnlein, K Reich
| DOI https://doi.org/10.25251/skin.4.supp.84

Page s84

Poster PDF

Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT

A Blauvelt, AB Gottlieb, F Fierens, F Brock, S Wiegratz, H Sofen
| DOI https://doi.org/10.25251/skin.4.supp.85

Page s85

Poster PDF

Acne & Rosacea

Efficacy and Safety of Narrow-spectrum Oral Sarecycline for Moderate to Severe Acne Vulgaris

Angela Moore, Lawrence J. Green, Jodi L. Johnson, Ayman Grada
| DOI https://doi.org/10.25251/skin.4.supp.86

Page s86

Poster PDF

Long-term Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study

David M Pariser, Lawrence J. Green, Edward L. Lain, Jodi L. Johnson, Ayman Grada
| DOI https://doi.org/10.25251/skin.4.supp.87

Page s87

Poster PDF

Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race

Fran E Cook-Bolden, Neal Bhatia, Jonathan S Weiss, Neil Sadick, Stephen K Tyring, Eric Guenin, Anya Loncaric, Susan Harris
| DOI https://doi.org/10.25251/skin.4.supp.88

Page s88

Poster PDF

Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients

James Del Rosso, Linda Stein Gold, Leon Kircik, Andrew Alexis, Seemal R. Desai, Vassilis Stakias, Iain Stuart
| DOI https://doi.org/10.25251/skin.4.supp.89

Page s89

Poster PDF

A Prospective, Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination Of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne

James Q Del Rosso, Linda Stein Gold, Zoe Draelos, Tooraj Joseph Raoof, Deidre Hooper, Iain Stuart
| DOI https://doi.org/10.25251/skin.4.supp.90

Page s90

Poster PDF

Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea

Linda Stein Gold, James Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart
| DOI https://doi.org/10.25251/skin.4.supp.91

Page s91

Poster PDF

Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies

James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart
| DOI https://doi.org/10.25251/skin.4.supp.92

Page s92

Poster PDF

Atopic Dermatitis

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

Melinda J. Gooderham, Leon H. Kircik, Matthew Zirwas, Mark Lee, Steven E. Kempers, Zoe D. Draelos, Laura Ferris, Terry M. Jones, Etienne Saint-Cyr Proulx, Robert Bissonnette, Neal Bhatia, Scott T. Guenthner, Robert A. Koppel, Howard Welgus, Charlotte Merritt, Meg Elias, Lynn Navale, Robert C. Higham, Michael Droege, David R. Berk
| DOI https://doi.org/10.25251/skin.4.supp.93

Page s93

Poster PDF

Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements

E Guttman-Yassky, A Blauvelt, L Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson
| DOI https://doi.org/10.25251/skin.4.supp.94

Page s94

Poster PDF

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Michael E. Kuligowski, May E. Venturanza, Kang Sun, Eric L. Simpson
| DOI https://doi.org/10.25251/skin.4.supp.95

Page s95

Poster PDF

Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)

Eric Simpson, Andrew Blauvelt, Emma Guttman-Yassky, Margitta Worm, Charles Lynde, Hidehisa Saeki, Yves Poulin, Andreas Wollenberg
| DOI https://doi.org/10.25251/skin.4.supp.96

Page s96

Poster PDF

Efficacy and Safety of Tralokinumab with Concomitant Topical Corticosteroids in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of the ECZTRA 3 Trial

Boni E. Elewski, Matthew J. Zirwas, Richard G. Langley, Andrew F. Alexis, Karen A. Veverka, John Zoidis, Azra Kurbasic, Jonathan I. Silverberg
| DOI https://doi.org/10.25251/skin.4.supp.97

Page s97

Poster PDF

Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg, Michael Cork, Andreas Wollenberg, Norito Katoh, Louise Abildgaard Steffensen, Azra Kurbasic, Christina Kurre Olsen, Alexandra Kuznetsova, Marie Louise ?sterdal, Andreas Westh Vilsb?ll, Mette Deleuran
| DOI https://doi.org/10.25251/skin.4.supp.98

Page s98

Poster PDF

Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

Jonathan Silverberg, Andrew Pink, Christina Olsen, Stephan Weidinger
| DOI https://doi.org/10.25251/skin.4.supp.99

Page s99

Poster PDF

Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis

Stephan Weidinger, Andrew Pink, Juan Francisco, Azra Kurbasic, Christina Olsen, Andreas Vilsb?ll, Marjolein de Bruin Weller
| DOI https://doi.org/10.25251/skin.4.supp.100

Page s100

Poster PDF

Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Regional Differences in Baseline Disease Characteristics and Prior Treatment in the ECZTRA 1 and ECZTRA 2 Trials

Eric Simpson, Thomas Werfel, Thomas Bieber, Louise Steffensen, Alexandra Kuznetsova, Marie ?sterdal, Hidehisa Saeki
| DOI https://doi.org/10.25251/skin.4.supp.101

Page s101

Poster PDF

Compatibility of a Colloidal Oatmeal Containing Body Wash for Pediatric Subjects with Atopic Dermatitis

CE Arrowitz, L Jiang, PD Hino, TM Weber
| DOI https://doi.org/10.25251/skin.4.supp.103

Page s103

Poster PDF

Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

Stephan Weidinger, Jonathan Silverberg, Darryl Toth, Thomas Bieber, Andrew Alexis, Boni Elewski, Andrew Pink, DirkJan Hignen
| DOI https://doi.org/10.25251/skin.4.supp.102

Page s102

Poster PDF

Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis

Michael Cork, Diamant Tha?i, Lawrence Eichenfield, Peter Arkwright, Zhen Chen, Mohamed Kamal, John O'Malley, Ashish Bansal
| DOI https://doi.org/10.25251/skin.4.supp.104

Page s104

Poster PDF

Atopic Dermatitis (AD) Disease History With AD Treatment History in a Cohort of AD Patients Treated With Dupilumab From a Real-World Registry (PROSE)

Tien Nguyen, Hermenio Lima, Lindsey Finklea, Haixin Zhang, Daniel Richman, Andrew Korotzer, Shikha Bansal
| DOI https://doi.org/10.25251/skin.4.supp.105

Page s105

Poster PDF

Baseline Characteristics of Atopic Dermatitis (AD) and AD Treatments in a Cohort of Adult AD Patients Initiating Dupilumab in a Real-World Registry (PROSE)

Daniel Shrager, Scott Guenthner, David Cohen, Haixin Zhang, Daniel Richman, Andrew Korotzer, Shikha Bansal
| DOI https://doi.org/10.25251/skin.4.supp.106

Page s106

Poster PDF

Dermatopharmacology

Reduced Blood-brain Barrier Penetration of Sarecycline Relative to Minocycline in Rats Corresponds with Lipophilicity and Low Vestibular Side Effects

Linda Stein-Gold, Angela Moore, S. Ken Tanaka, Jodi Johnson, Ayman Grada
| DOI https://doi.org/10.25251/skin.4.supp.107

Page s107

Poster PDF

Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors

Anjaneya Chimalakonda, James Burke, Lihong Cheng, Ian Catlett, Aditya Patel, Jun Shen, Ihab Girgis, Subhashis Banerjee, John Throup
| DOI https://doi.org/10.25251/skin.4.supp.108

Page s108

Poster PDF

A Four-Way, Cross-Over Design, Randomized, Double-Blinded, Placebo-&Active-Controlled Study for the Evaluation of the Effect of a Supratherapeutic Dose of Sofpironium Bromide Gel, 15% Applied Topically on the QT/QTc Intervals in Adult Healthy Volunteers

Brandon Kirsch, Danielle Armas, Deepak Chadha
| DOI https://doi.org/10.25251/skin.4.supp.109

Page s109

Poster PDF

Review of Mechanisms of Release of Commonly Prescribed Tetracyclines

Pearl Kwong, Hilary Baldwin, Debbie Glaab, Rhonda Schreiber, Emma Hignett
| DOI https://doi.org/10.25251/skin.4.supp.110

Page s110

Poster PDF

Incidence, Characteristics, and Management of Alpelisib-Associated Rash in Patients With Advanced Breast Cancer

Anisha Patel, Lucia Seminario-Vidal
| DOI https://doi.org/10.25251/skin.4.supp.111

Page s111

Poster PDF

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

Caroline Robert, Jean Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Dirk Schadendorf, Georgina Long
| DOI https://doi.org/10.25251/skin.4.supp.112

Page s112

Poster PDF

A Comparative Clinical Demonstration of the Spreadability of Tazarotene Lotion 0.045% versus Trifarotene Cream 0.005%

Zoe Draelos, Emil Tanghetti
| DOI https://doi.org/10.25251/skin.4.supp.113

Page s113

Poster PDF

Hyperhidrosis

A Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children/Adolescents, 9-16 Years, with Primary Axillary Hyperhidrosis

Brandon Kirsch, Janet Dubois, Martin Zaiac, Sanjeev Ahuja, Deepak Chadha
| DOI https://doi.org/10.25251/skin.4.supp.116

Page s116

Poster PDF

Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents

ZP Rice, LJ Pieretti, A Wheeler, J Payne, KK Gillard, AA Hebert
| DOI https://doi.org/10.25251/skin.4.supp.117

Page s117

Poster PDF

Depression, Anxiety, Health Care Costs, and Utilization among Patients with Hyperhidrosis in a Real‑World Database Analysis

M Hull, KK Gillard, J Peterson-Brandt, SZ Klein
| DOI https://doi.org/10.25251/skin.4.supp.118

Page s118

Poster PDF

Skin Cancer

Phase I Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects with Actinic Keratosis

Regina Yavel, J. Scott Overcash, Jay Zhi, Eva Cutler, David Cutler, Jane Fang
| DOI https://doi.org/10.25251/skin.4.supp.119

Page s119

Poster PDF

Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.4.supp.120

Page s120

Poster PDF

Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies

Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan
| DOI https://doi.org/10.25251/skin.4.supp.121

Page s121

Poster PDF

Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Michael Migden, Danny Rischin, Medha Sasane, Vera Mastey, Anna Pavlick, Chrysalyne Schmults, Zhen Chen, Alexander Guminski, Axel Hauschild, Denise Bury, Anne Lynn Chang, Guilherme Rabinowits, Sheriff Ibrahim, Israel Lowy, Matthew Fury, Siyu Li, Chieh-I Chen
| DOI https://doi.org/10.25251/skin.4.supp.122

Page s122

Poster PDF

Patterns Of Hedgehog Inhibitor (HHI) Treatment Interruptions and Reinitiations Among Patients with Basal Cell Carcinoma (BCC) in Real-World Clinical Practice

Jessica Jalbert, Chieh-I Chen, Ning Wu, Matthew Fury, Wenzhen Ge, Emily Ruiz
| DOI https://doi.org/10.25251/skin.4.supp.123

Page s123

Poster PDF

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

Danny Rischin, Nikhil Khushalani, Chryslalyne Schmults, Alexander Guminski, Anne Lynn Chang, Karl Lewis, Annette Lim, Leonel Hernandez-Aya, Brett Hughes, Dirk Schadendorf, Axel Hauschild, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Zhen Chen, Emmanuel Okoye, Israel Lowy, Matthew Fury, Micahel Migden
| DOI https://doi.org/10.25251/skin.4.supp.124

Page s124

Poster PDF

Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Guilherme Rabinowits, Jade Homsi, Mina Nikanjam, Rhonda Gentry, John Strasswimmer, Suraj Venna, Michael Migden, Sunandana Chandra, Emily Ruiz, Haixin Zhang, Jennifer McGinniss, Alex Seluzhytsky, Jigar Desai
| DOI https://doi.org/10.25251/skin.4.supp.125

Page s125

Poster PDF

Combining DNA and RNA Analyses Enhances Non-Invasive Early Detection of Cutaneous Melanoma

Stepnaie Cullison, Laura Ferris, Zuxu Yao, Claudia Ibarra, Michael Howell, Burkhard Jansen
| DOI https://doi.org/10.25251/skin.4.supp.126

Page s126

Poster PDF

Miscellaneous

The Synergistic, Amplifying Use of Micronized Purified Flavanoid Fraction, Proprietary Ceramide Emulsion, and Dermal Microdeformation Fuzzy Wale Compression Under Inelastic Compression for the Management of Venous Leg Ulcers

Matthew Melin, Jennifer Reinders, Angie Wubben, Katie Cecconi
| DOI https://doi.org/10.25251/skin.4.supp.114

Page s114

Poster PDF

Step-up Therapy with Skin Barrier Repair Emulsion in Personal Protective Equipment (PPE) Associated Adverse Skin Reactions during the COVID-19 Pandemic

Katlyn Anderson
| DOI https://doi.org/10.25251/skin.4.supp.115

Page s115

Poster PDF